Literature DB >> 11793128

Adolescent hemodialysis: results of the 2000 ESRD Clinical Performance Measures Project.

Diane L Frankenfield1, Alicia M Neu, Bradley A Warady, Sandra L Watkins, Aaron L Friedman, Barbara A Fivush.   

Abstract

In 2000, the Centers for Medicare and Medicaid Services (CMS), formerly known as the Health Care Financing Administration (HCFA) 2000 ESRD Clinical Performance Measures (CPM) Project, was expanded to obtain demographic characteristics and clinical information on all adolescent (age > or =12 years, <18 years) patients receiving in-center hemodialysis on 31 December, 1999. Of the 486 patients identified, 433 (89%) had the minimum required data submitted. Demographic characteristics included mean age of 15.8 years (+/-1.6 years). Forty-nine percent were white, 42% black; 21% were Hispanic. Congenital/urologic disease and focal and segmental sclerosis were the leading causes of end-stage renal disease. Forty-one percent had a catheter as their dialysis access, while 37% had an AV fistula and 22% an AV graft in place. The mean Kt/V was 1.47 (+/-0.38) and 79% had a mean calculated Kt/V> or =1.2, although residual renal function was not included in this measurement. After multivariate logistic regression, male gender and black race were among the factors predictive of mean calculated Kt/V<1.2. The mean serum albumin was 3.85 g/dl (+/-0.51) in patients with bromcresol green measurements and 3.62 mg/dl (+/-0.52) in patients with bromcresol purple measurements. The mean hemoglobin was 10.99 g/dl (+/-1.6) and 55% had a mean hemoglobin > or =11 g/dl. After multivariate logistic regression, lower epoetin dose and mean serum albumin > or =3.5/3.2 g/dl (BCG/BCP) remained predictive of mean hemoglobin > or =11 g/dl. These data provide important information about the clinical status of adolescent hemodialysis patients in the United States. Continued data collection and analyses are planned to identify areas for potential improvement in patient care.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11793128     DOI: 10.1007/s004670200002

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  4 in total

1.  Anemia in pediatric dialysis patients in end-stage renal disease network 5.

Authors:  Jeffrey J Fadrowski; Susan L Furth; Barbara A Fivush
Journal:  Pediatr Nephrol       Date:  2004-07-06       Impact factor: 3.714

2.  Morbidity and mortality in children with anemia at initiation of dialysis.

Authors:  Bradley A Warady; Martin Ho
Journal:  Pediatr Nephrol       Date:  2003-07-23       Impact factor: 3.714

3.  Iron therapy in the pediatric hemodialysis population.

Authors:  Bradley A Warady; Annamaria Kausz; Gary Lerner; Eileen D Brewer; Vimal Chadha; Carlo Brugnara; Naomi V Dahl; Sandra L Watkins
Journal:  Pediatr Nephrol       Date:  2004-04-03       Impact factor: 3.714

Review 4.  Clinical outcomes in pediatric hemodialysis patients in the USA: lessons from CMS' ESRD CPM Project.

Authors:  Alicia M Neu; Diane L Frankenfield
Journal:  Pediatr Nephrol       Date:  2008-05-29       Impact factor: 3.714

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.